Rev. OFIL 2017, 27;2:201-204
Fecha de recepción: 01/07/2016 – Fecha de aceptación: 14/07/2016
González Freire L, Dávila Pousa MC, Crespo Diz C
Servicio de Farmacia. Complexo Hospitalario Universitario de Pontevedra. Pontevedra (España)
Lara González Freire
Avda. de Montecelo, s/n
36071 Mourente (Pontevedra)
Correo electrónico: firstname.lastname@example.org
The vernal keratoconjunctivitis (VKC) is a severe seasonal allergic conjunctivitis that occurs mainly in children under the age of ten. Its basic treatment consists of topical anti-allergics, nonsteroidal anti-inflammatories (NSAIDs) such corticosteroids. In case of resistance the cyclosporine can be used.
Tacrolimus is a macrolide immunosuppressive drug that inhibits the phosphates of the calcineurin in a more powerful way than the cyclosporine. Its benefit at a topical ocular level has been demonstrated in different pathologies, including VKC.
We are going to describe the case of a six years old pediatric patient who has been diagnosed with VKC three years ago. The elaboration of an eye drop and an ophthalmic tacrolimus ointment was requested.
After an intensive study and a literature review on the different formulations, we decided to begin the treatment with an 0,03% tacrolimus eye drops in order to prove the tolerance and the response to its concentration. After 6 months of treatment, the patient showed a sustained response with adequate tolerance without needing to receive any other concomitant treatment.
Key Words: Tacrolimus, keratoconjunctivitis, eye drops.